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by acute intravenous amphetamine: role of dopamine receptors
and individual differences in amphetamine self-administration
Submitted April 1998; revised October 1998; published January 1999.
Abstract Although previous studies have shown that dopamine
(DA) antagonists block amphetamine reward, these studies have
utilized animal models that involve repeated exposures to amphetamine. The present investigation examined the effect of DA antagonists on single-trial conditioned place preference (CPP) produced
by acute intravenous (IV) amphetamine in rats. In the first experiment, rats were prepared with a jugular catheter and then received
an acute IV injection of amphetamine (0.1–3 mg/kg) paired with
one compartment of a CPP apparatus. Relative to sham controls (no
IV catheter), amphetamine produced a dose-dependent increase in
locomotor activity and CPP. Two further experiments demonstrated that both effects of amphetamine were completely blocked by
pretreating rats with the D1 DA antagonist SCH-23390 (0.025 and
0.25 mg/kg) or the D2 DA antagonist eticlopride (0.2 and 2 mg/kg)
on the conditioning trial. In a final experiment, single-trial amphetamine CPP did not predict subsequent self-administration of IV amphetamine (10–50 μg/infusion) using either a fixed ratio (FR) 1 or
progressive ratio (PR) schedule of reinforcement. Thus, while sharing a similar DA receptor mechanism, the present results indicate
that single-trial CPP and self-administration are dissociable effects
of IV amphetamine.
Keywords Amphetamine • Dopamine • Locomotor
activity • Conditioned place preference •
Self administration • Dopamine receptor
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Introduction
Clinical evidence suggests that vulnerability to drug abuse may be
predicted by the degree of positive reward derived from the initial
drug experience (Haertzen et al. 1983). Individual differences in the
acute rewarding effect of various drugs of abuse probably reflect, at
least in part, neuropharmacological differences related to both genetic and environmental factors. Unfortunately, investigations into
the neuropharmacological mechanisms that underlie acute drug reward are lacking. In humans, most studies of drug reward involve
subjects that have an extensive history of drug-taking. Similarly,
animal models of drug reward, such as conditioned place preference (CPP) or self-administration (Yokel 1987; Carr et al. 1989),
typically require repeated drug exposures. Since repeated drug exposure may produce either tolerance or sensitization to the behavioral effect of various drugs (Stewart and Badiani 1993; Ramsay
and Woods 1997; Schenk and Partridge 1997), these approaches do
not allow for assessment of the neuropharmacological mechanisms
of acute drug reward.
One potential strategy to assess acute drug reward in laboratory
animals is to utilize the single-trial CPP procedure. Although CPP
typically requires multiple drug conditioning trials, evidence indicates that acute IV injection of a relatively high dose of morphine
(4–8 mg/kg) induces CPP in rats (Mucha et al. 1982; Bardo and
Neisewander 1986). This preference is established by rapidly infusing the drug at the beginning of a 30-min placement into a distinct
stimulus compartment. On the next day, rats are given equivalent
exposure (without drug) to a different stimulus compartment. When
rats are subsequently allowed to choose between the two compartments, they show a preference for the drug compartment relative to
the no-drug compartment. Establishment of this CPP is blocked by
naloxone (Bardo and Neisewander 1986), indicating that opiate receptors mediate acute morphine reward. At present, it is unclear if
single-trial CPP is unique to opiates or whether it may also be obtained with other drug classes.
The major purpose of the present study was to determine if IV
amphetamine produces single-trial CPP and to assess if this effect
is blocked by dopamine (DA) antagonists selective for either the
D1 receptor family (D1 and D5) or the D2 receptor family (D2, D3
or D4). Previous work has shown that amphetamine reward is attenuated by either D1 or D2 DA antagonists (Yokel and Wise 1975;
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Spyraki et al. 1982; Hoffman and Beninger 1989). In all of these
studies, however, amphetamine reward was assessed with repeated drug treatment in either a CPP or self-administration model. It
is well known that repeated amphetamine treatment induces behavioral sensitization and alters activity of the mesolimbic DA system
(Robinson and Becker 1986; Kalivas et al. 1993; Cador et al. 1995;
Segal and Kuczenski 1997). Thus, it not clear if the antagonist-induced attenuation in amphetamine reward would also be obtained
in a non-sensitized animal model. A secondary purpose of the present study was to determine if the acute rewarding effect of IV amphetamine, assessed by single-trial CPP, predicts subsequent amphetamine abuse liability, assessed by repeated self-administration.

was separate from the colony room and was equipped with a white
noise generator and audio speaker (ambient background of 70 dB).
Suspended from the ceiling above the apparatus was a video camera which was used to record the experimental sessions.
For assessment of amphetamine self-administration, 12 operant chambers (ENV-001; Med Associates, St Albans, Vt., USA)
enclosed in a sound attenuating environment were used. Located
in the bottom center of the front panel in each chamber was a 5×
4.2 cm opening to a recessed food tray. Two metal response levers
were located on the front panel, one on each side of the food tray.
The center of each lever was mounted 7.3 cm from the grid floor. A
28-V cue light, 3 cm in diameter, was centered 6 cm above each lever. Drug infusions were delivered using a syringe pump (Med Associates; PHM-100) and a water-tight swivel that allowed a catheter to be attached from the syringe (10 ml) to the head mount of
the animal in the operant chamber. A personal computer, using Med
Associates interface, controlled the experimental sessions and collected data.

Materials and methods
Animals
Adult male Sprague-Dawley rats (200–225 g body weight) were
obtained from Harlan Industries (Indianapolis, Ind., USA) and were
caged individually with free access to food and water in the home
cage. The colony room was controlled for temperature (24°C) and
relative humidity (45%), with lights on from 0700 to 1900 hours.
Prior to the start of each experiment, animals were acclimated to
the colony room for at least 1 week and were handled for 2 days.
Behavioral testing was conducted during the light phase of the cycle. All procedures were approved by the University of Kentucky
Institutional Animal Care and Use Committee.
Surgery
Animals were anesthetized (100 mg/kg ketamine, 5 mg/kg diazepam, IP) and implanted with a catheter into the jugular vein. In the
CPP experiments that required only a single injection of amphetamine, a polyethylene tube (PE-50) was inserted into the vein and
exited out the mid-scapular region of the back. A sterile piece of
stainless steel tubing was used to close the ending. Sham controls
received the same surgical treatment, but they did not receive the
catheter insertion. In the self-administration experiments that required repeated injections of amphetamine, a Silastic tube was inserted into the vein and exited out the top of a head mount that was
affixed to the top of the skull with dental acrylic and metal screws.
Daily infusions of heparinized saline and streptokinase (Pharmacia,
Columbus, Ohio, USA; 250 000 IU, 2 mg/ml heparinized saline,
0.1 ml/rat per day) were used to maintain patency of the Silastic
catheter. At the end of each experiment, each animal was injected
with IV morphine (15 mg/kg) and presence of a rapid cataleptic response was used to confirm catheter patency.
Apparatus
For assessment of locomotor activity and CPP, two similar conditioning apparatus were used. Each apparatus had three different
wooden compartments separated by removable partitions. The two
end compartments measured 24× 30× 45 cm high, while the middle compartment was smaller and measured 24× 10× 45 cm high.
One end compartment had white walls, a wire mesh floor, and pine
bedding beneath the floor. The other end compartment had black
walls, a metal rod floor, and cedar bedding beneath the floor. The
middle compartment had gray walls and a solid wood floor. The
solid partitions could be replaced with similar partitions containing a 10× 10 cm opening, which allowed the animals access to all
compartments. The apparatus was located in a laboratory room that

Behavioral procedures
For CPP, the conditioning procedure was conducted over 2 consecutive days. Because preliminary data from our laboratory indicated that drug-naive animals tend to show a slight preference for the
black compartment, amphetamine conditioning was established in
the white compartment. On day 1, animals were placed individually
into either the white or black compartments (counterbalanced within treatment groups) for 30 min with the solid partitions inserted
between the compartments. On day 2, animals received equal exposure to the opposite compartment. Conditioned animals were injected IV with amphetamine immediately following placement into
the white compartment and were injected with saline immediately
following placement into the black compartment. Control animals
received either no injection in either compartment (sham control)
or received saline in both compartments (saline control). To assess
the effect of antagonist drugs (SCH23390 or eticlopride), the 2-day
conditioning procedure was similar, except that the antagonist drug
was administered IV 5 min before placement into the white compartment. Locomotor activity in the white compartment was videotaped and later scored by an observer who was unaware of each animal’s individual treatment. Locomotor activity was quantified by
counting the number of times that each animal crossed over a line
drawn on the video monitor screen that bisected the white compartment in the plane parallel to the end wall. A line cross was operationally defined as both front shoulders crossing the line.
On the day following the 2-day conditioning procedure, each animal was tested for CPP. The rat was placed into the center gray
compartment and allowed to enter all compartments of the apparatus for 15 min. Test sessions were videotaped and the duration spent
in each compartment was determined by an observer who was unaware of each animal’s individual treatment. Entry into a compartment was operationally defined as having both front shoulders in
the compartment.
To assess the potential correlation between single-trial amphetamine CPP and amphetamine self-administration, a group of rats
were run in both behavioral procedures. Rats were first implanted
with a Silastic jugular catheter exiting through a head mount. After 2 days of recovery, each animal was assessed for CPP with a
single dose of amphetamine (1 mg/kg, IV) as described previously, except that rats were first given a 15-min preference test prior to
conditioning to establish the baseline preference for each compartment. A baseline preference test was used in this experiment in or-
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der to obtain a measure of amphetamine CPP from all rats in the
sample, i.e., no rats were assigned to a saline control group. Following baseline testing, amphetamine was subsequently paired
with the non-preferred compartment and saline was paired with
the preferred compartment. Following this conditioning procedure,
rats were again tested for place preference. The magnitude of amphetamine CPP for each individual rat was expressed as a percent
change in duration spent in the non-preferred compartment from
the preconditioning test to the post-conditioning test.
On the day following the single-trial CPP test, daily amphetamine self-administration sessions (3 h/session) were initiated. Rats
were first trained to self-administer amphetamine (30 μg/infusion,
0.1 ml/infusion, 10 s infusion) on a fixed ratio (FR) 1 schedule using a two-lever choice procedure. Depression of one lever delivered amphetamine and depression of the other lever led to no reinforcement; the levers were counterbalanced for drug reinforcement
across rats. Training continued until stable responding on the FR1
was established. Stable responding was defined as 15% or less variability in the number of responses on the drug lever across three
consecutive sessions. After this criterion was reached, each rat was
tested for self-administration of the training dose of amphetamine
(30 μg/infusion) on a progressive ratio (PR) schedule of drug reinforcement across three consecutive sessions (5 h/session). Within each PR session, the number of responses required to obtain an
amphetamine infusion increased incrementally (1, 2, 4, 6, 9, 12,
15, 20, etc.; see Roberts and Richardson 1992). The last ratio value
completed for amphetamine infusion within each session was defined as the breakpoint. After the breakpoint value was determined
using 30 μg amphetamine, rats were tested with two other amphetamine doses (10 and 50 μg/infusion) across consecutive daily sessions. For each dose, rats were first stabilized on an FR1 schedule
and then were tested for PR responding as described previously.
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dicted subsequent amphetamine self-administration, a CPP score
was derived for each animal by subtracting the duration spent in the
non-preferred compartment prior to conditioning from the duration
spent in the non-preferred compartment after conditioning. Pearson product-moment correlation coefficients were then derived by
correlating the shift in preference with the number of infusions on
the FR1 and PR schedules. Separate correlation coefficients were
determined for each self-administration test dose of amphetamine
(10, 30 and 50 μg/infusion).

Results
Amphetamine dose-effect curves
Separate groups of rats (n=9–16/group) were conditioned with a
single dose of amphetamine (0.1, 0.3, 1 or 3 mg/kg) or received
no injections (sham control). Within this dose range, there was a
dose-dependent increase in locomotor activity [F(4,46 )=15.80,
P<0.0001], with an apparent maximal increase at 1 mg/kg amphetamine (see Fig. 1A). Pairwise comparisons between groups revealed that, relative to the sham control, there was a significant increase in activity following 0.3, 1 and 3 mg/kg amphetamine, but
not following 0.1 mg/kg amphetamine.
As shown in Fig. 1B, there was also a significant dose-dependent CPP with amphetamine [F(4,48)=11.46, P<0.0001]. Pairwise
comparisons between groups revealed that, relative to the sham
control, there was a significant increase in preference following 1

Drugs
Amphetamine sulfate and morphine sulfate were obtained from the
National Institute on Drug Abuse (Rockville, Md., USA); R(+)SCH-23390 hydrochloride and S(–)-eticlopride hydrochloride
were purchased from Research Biochemicals International (Natick,
Mass., USA); ketamine hydrochloride (100 mg/ml injectable) was
purchased from Fort Dodge Laboratories (Fort Dodge, Iowa, USA);
and diazepam (5 mg/ml injectable) was purchased from Steris Laboratories (Phoenix, Ariz., USA). For CPP, drugs were prepared in
sterile heparinized saline (0.9% NaCl) and injected IV in a volume
of 1 ml/kg body weight. For self-administration, amphetamine was
prepared in sterile saline and injected IV in a volume of 0.1 ml/infusion. All dosages were calculated using the salt form of the drug.
Statistics
In all of the single-trial CPP experiments, locomotor activity and
preference data were analyzed by separate factorial analyses of
variance (ANOVAs). Pairwise comparisons among treatment
groups were performed using Tukey’s HSD test (Kirk 1968). In
these analyses, CPP data were expressed as either an absolute measure of preference (total duration in white compartment) or a relative measure of preference (total duration in white compartment
divided by total duration in white+black compartments). However, since these two measures yielded essentially equivalent results
across experiments, only the absolute preference data are presented in graphic form.
To determine if individual differences in amphetamine CPP pre-

Fig. 1A, B Dose-effect curves for locomotor activity and CPP with
acute IV amphetamine. A Mean level of activity (±SEM) measured
in the white compartment immediately following amphetamine or
sham injection. B Duration of time spent in the drug-paired white
compartment on the test day following single-trial amphetamine
conditioning. In both panels, an asterisk (*) represents a significant
difference from the sham control group and a hash (#) represents
a significant difference from 1 mg/kg amphetamine group [Tukey’s
test, P<0.05]
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Fig. 2A–D Effect of varying doses of SCH-23390 or eticlopride on locomotor activity and CPP produced by acute IV amphetamine (1 mg/
kg). A Mean level of activity (±SEM) on the conditioning day in rats
pretreated with SCH-23390 or saline and then placed in the white compartment following either amphetamine (hatched columns) or saline
(clear columns). B Mean level of activity (±SEM) on the conditioning
day in rats pretreated with eticlopride or saline and then placed in the
white compartment following either amphetamine or saline. C Duration of time spent in the drug-paired compartment on the test day in
rats previously pretreated with SCH-23390 or saline on the conditioning day with amphetamine or saline. D Duration of time spent in the
drug-paired compartment on the test day in rats previously pretreated
with eticlopride or saline on the conditioning day with amphetamine or
saline. In all panels, an asterisk (*) represents a significant difference
from the saline conditioned group pretreated with the same dose of antagonist (Tukey’s test, P<0.05)

[F(7,76)= 10.71, P<0.0001]. In saline-pretreated animals, amphetamine produced a significant increase in activity. This amphetamine-induced increase was not significantly altered by the lowest dose of SCH-23390 (0.0025 mg/kg). Pretreatment with 0.025
mg/kg SCH-23390 blocked the locomotor stimulant effect of amphetamine; this dose of SCH-23390 did not significantly decrease
activity in saline controls. At the highest pretreatment dose of
SCH23390 (0.25 mg/kg), locomotor activity was almost completely depressed in both amphetamine and saline conditioned groups.
As shown in Fig. 2C, SCH-23390 also blocked amphetamine
CPP. The overall ANOVA for CPP revealed a significant interaction
between conditioning drug (amphetamine or saline) and pretreatment dose of SCH23390 [F(7,76)=44.45, P<0.0001]. With saline
pretreatment, amphetamine conditioned animals showed a preference for the drug-paired compartment relative to saline controls.
This amphetamine CPP was not significantly altered by the lowest
dose of SCH-23390 (0.0025 mg/kg). Pretreatment with either 0.025
or 0.25 mg/kg SCH-23390 blocked the amphetamine CPP. Pretreatment with SCH-23390 alone (open bars in Fig. 2C) also tended to
increase preference; however, none of the SCH23390 alone groups
differed significantly from saline control.
Similar to SCH-23390, pretreatment with eticlopride decreased
the locomotor stimulant effect of amphetamine (see Fig. 2B). The
overall ANOVA revealed a significant interaction between conditioning drug (amphetamine or saline) and pretreatment dose of eticlopride [F(7,77)=42.67, P<0.0001]. In saline pretreated animals,
amphetamine produced a marked increase in activity. This amphetamine-induced increase was blocked by the lowest dose of eticlopride (0.02 mg/kg). Higher pretreatment doses of eticlopride (0.2
and 2 mg/kg) also blocked the locomotor stimulant effect of amphetamine. Although the high eticlopride doses also decreased activity in saline controls, these differences did not reach statistical
significance.

and 3 mg/kg amphetamine, but not following either 0.1 or 0.3 mg/
kg amphetamine. There was also a significant difference between
groups conditioned with either 1 or 3 mg/kg amphetamine.
Effects of DA antagonists
To assess the role of DA receptor subtypes in the acute effects of
IV amphetamine, separate groups of rats (n=8–10/group) were pretreated with either the D1 antagonist SCH-23390 (0, 0.0025, 0.025
or 0.25 mg/kg) or the D2 antagonist eticlopride (0, 0.02, 0.2 or 2
mg/kg) prior to conditioning with amphetamine (1 mg/kg) or saline. As shown in Fig. 2A, SCH-23390 decreased the locomotor
stimulant effect of amphetamine. The overall ANOVA for locomotor activity revealed a significant interaction between conditioning
drug (amphetamine or saline) and pretreatment dose of SCH-23390
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Fig. 3A, B Dose-effect curves for IV amphetamine self-administration using either an FR1 A or PR B schedule of reinforcement.
The mean PR breakpoint values corresponding to the amphetamine
doses of 10, 30 and 50 g/infusion were 9, 28.5 and 60, respectively.
Significant dose-dependent differences in the number of infusions
were obtained on both the FR1 and PR schedules (Ftest, P<0.05)

Fig. 4A, B Relationship between single-trial CPP using IV amphetamine (1 mg/kg) and self-administration of IV amphetamine (30 g/
infusion). A Scatterplot of individual data points and a best-fit line
derived from rats tested for amphetamine CPP and self-administration on a FR1 schedule. B Scatterplot of individual data points and
a best-fit line derived from rats tested for amphetamine CPP and
self-administration on a PR schedule. In both panels, the degree of
relationship was not significant (Pearson r, P>0.05)

As shown in Fig. 2D, eticlopride blocked amphetamine CPP.
The overall ANOVA revealed a significant interaction between conditioning drug (amphetamine or saline) and pretreatment dose of
eticlopride [F(7,77)= 7.33, P<0.0001]. With saline pretreatment,
amphetamine-conditioned animals showed a preference for the
drug-paired compartment relative to saline controls. Amphetamine
CPP was also evident in animals pretreated with 0.02 mg/kg eticlopride, but not in animals pretreated with either 0.2 or 2 mg/kg eticlopride. Pretreatment with either 0.2 or 2 mg/kg eticlopride alone
(open bars in Fig. 2D) produced a significant increase in preference
compared to saline control.

of 99.3 s (data not shown); this within-subject preference shift was
statistically significant [F(1,16)=19.22, P<0.001]. Examination of
the self-administration group data, displayed in Figs. 3A and B,
revealed that the number of infusions varied as a function of amphetamine dose on the FR1 schedule [F(2,10)=118.62, P<0.0001]
and the PR schedule [F(2,10)=7.87, P<0.01]. There was no significant relationship between amphetamine CPP and number of amphetamine infusions at any dose on either the FR1 or PR schedule.
Scatterplots of the data from the training dose of amphetamine (30
μg/infusion) are presented in Figs. 4A and B.

Individual differences in amphetamine CPP
and self-administration
Individual differences in single-trial amphetamine CPP and amphetamine self-administration were correlated in a group of rats
(n=17) that were assessed in both behavioral procedures as described previously. Examination of the CPP group data revealed
that the shift in preference for the non-preferred compartment after conditioning ranged from –81 to 290 s, with an average shift

Discussion
Previous work has demonstrated that single-trial CPP is obtained
following acute IV morphine (Mucha et al. 1982; Bardo and Neisewander 1986). The present results indicate that single-trial CPP
is not specific to opiate drugs, but that it is also evident following
acute IV amphetamine. The amphetamine dose-effect curve for single-trial CPP was graded within the dose range tested (0.1–3 mg/
kg). Within a similar dose range, other studies have shown that the
dose-effect curve for multiple-trial CPP following IP or SC injec-
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tions of amphetamine is also graded (Bardo et al. 1995). These results counter the argument that CPP as a measure of drug reward is
relatively insensitive to drug dosage (Wise 1989). Despite the graded effect, however, it should be noted that a plateau in the dose-effect curve defining the maximal conditioning effect was not apparent in the present study. Doses higher than 3 mg/kg amphetamine
were not tested because of the potential for seizures, as well as evidence indicating that higher doses given repeatedly may produce a
conditioned place aversion (Bardo et al. 1995).
In contrast to the present results, at least one report found that
acute IV cocaine does not induce single-trial CPP (Nomikos and
Spyraki 1988). While this finding suggests that single-trial CPP
may not generalize to all stimulant drugs, procedural differences between the cocaine study conducted by Nomikos and Spyraki
(1988) and the present amphetamine study may account for the differential outcomes. First, Nomikos and Spyraki (1988) tested only
a single dose of cocaine (0.5 mg/kg), whereas the present report
tested a full range of amphetamine doses (0.1–3 mg/kg). Second,
Nomikos and Spyraki (1988) injected the rats outside of the conditioning apparatus, whereas the present report injected the rats inside
of the apparatus. Perhaps having the onset of the IV drug effect in
the test apparatus, rather than outside the apparatus, led to more robust conditioning in the present study. This possibility is supported
by other work showing backward pairing of a conditioned stimulus
(apparatus compartment) with an unconditioned stimulus (drug effect), as used in the Nomikos and Spyraki (1988) study, typically
produces negligible conditioning (Mackintosh 1974). Given these
procedural differences, it seems premature to conclude that IV cocaine CPP cannot be obtained with a single trial. Further parametric
work will be needed to resolve this issue.
Although there has been some debate in the literature about the
potential influence of conditioned locomotor responses on the expression of CPP (Swerdlow and Koob 1984; Carr et al. 1989), the
present results with IV amphetamine show a clear dissociation between locomotor activity and CPP. Most important, the dose-effect
curves for amphetamine-induced activity and CPP differed across
the dose range tested. The lowest dose of amphetamine that increased activity was a half-log unit lower than that needed to produce CPP. In addition, while a clear plateau in locomotor stimulation was evident at 1 mg/kg amphetamine, no plateau in CPP was
apparent up to 3 mg/kg amphetamine. These results suggest that,
although drugs of abuse may increase locomotor activity and produce reward by activating a similar DA substrate in the brain (Wise
and Bozarth 1987), expression of these different behaviors also involves some separate neuropharmacological mechanisms.
The present results also provide evidence about the role of D1
and D2 DA receptor families on the locomotor stimulant and rewarding effects of acute IV amphetamine. With locomotor activity, pretreatment with either SCH-23390 or eticlopride completely
blocked the locomotor activity induced by IV amphetamine. These
results are in accord with previous work showing that selective D1
and D2 DA antagonists are potent blockers of the hyperactivity observed with administration of acute amphetamine via other routes
(Beninger and Hahn 1983; Mithani et al. 1986; Stewart and Vezina 1987; Vezina and Stewart 1989; Mazurski and Beninger 1991).
Despite their similar blockade of hyperactivity following acute amphetamine, it is important to note that selective D1 and D2 DA antagonists also have a differential effect on the locomotor sensitization obtained with repeated amphetamine injections. That is,
amphetamine-induced locomotor sensitization is blocked by D1
antagonists, but not by D2 antagonists (Stewart and Vezina 1987;

Ujike et al. 1989; Vezina and Stewart 1989; Drew and Glick 1990).
These findings indicate that locomotor activity following acute amphetamine and locomotor sensitization following repeated amphetamine injections involves, at least in part, separate neuropharmacological mechanisms.
Similar to their effects on amphetamine-induced locomotion,
SCH-23390 or eticlopride pretreatments blocked completely the
CPP induced by acute IV amphetamine. These findings are consistent with previous work showing that both D1 and D2 receptors play
a role in amphetamine reward. In particular, pretreatment with selective D1 or D2 DA antagonists has been shown to attenuate amphetamine reward assessed by multiple-trial CPP (Spyraki et al.
1982; Mithani et al. 1986; Leone and Di Chiara 1987; Hoffman and
Beninger 1989; Hiroi and White 1991; Acquas and Di Chiara 1994)
and self-administration (Yokel and Wise 1975; Phillips et al. 1994).
In these previous studies, however, it is important to note that the
rewarding effect of amphetamine was assessed across repeated injections. Since the rewarding effect of amphetamine becomes sensitized across repeated administrations (Woolverton et al. 1984; Lett
1989; Strakowski et al. 1996), it is unclear if the antagonist effects
observed in these previous studies reflect either a blockade of the
acute rewarding effect of amphetamine or a blockade of the sensitization produced by repeated amphetamine injections. The present study directly addressed this issue by using a single-trial CPP
procedure that rules out the contribution of any sensitization that
occurs with repeated amphetamine injections. Since pretreatment
with either SCH-23390 or eticlopride blocked single-trial amphetamine CPP, these results provide evidence that both D1 and D2 DA
receptors mediate the primary rewarding effect induced by the first
amphetamine experience.
While it seems likely that SCH-23390 and eticlopride disrupted
single-trial amphetamine CPP by attenuating the acute rewarding
effect of amphetamine, we cannot rule out the possibility that these
antagonists may have impaired learning of the CPP behavior independent of any direct effect on amphetamine reward. In particular,
previous work has shown that SCH-23390 may disrupt learning in
various behavioral tasks across different species (Sanger 1987; Ichihara et al. 1989; Sawaguchi and Goldman-Rakic 1991). Perhaps
most relevant to the present study, Lin et al. (1994) examined the effect of SCH-23390 and raclopride on single-trial amphetamine conditioned taste aversion in rats. Like CPP, amphetamine conditioned
taste aversion is thought to involve the acquisition of a Pavlovian
association between a conditioned stimulus with amphetamine. In
the study by Lin et al. (1994), pretreatment with SCH-23390 or raclopride did not alter the conditioned taste aversion produced by
acute amphetamine. These results indicate that blockade of either
D1 or D2 DA receptors does not produce a generalized impairment
in the ability of animals to form a Pavlovian association between
a conditioned stimulus and amphetamine following a single trial.
Thus, it seems more likely that the DA antagonists used in the present report blocked the acute rewarding effect of amphetamine rather than impairing learning.
One unexpected finding from the present study was that eticlopride alone (no amphetamine) produced a significant preference for
the drug-paired compartment. A similar trend was observed with
SCH-23390. However, it is important to note that the DA antagonist doses that produced the apparent CPP also abolished activity
almost completely. This antagonist-induced immobility may have
prevented habituation to the stimulus compartment on the conditioning day, thus making the compartment relatively more novel on
the test day. Since rats prefer a novel compartment relative to a fa-
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miliar compartment (Bardo et al. 1989; Parker 1992), the apparent
antagonist-induced CPP observed here may reflect a preference for
novelty.
In addition to assessing the role of D1 and D2 DA receptors, the
present study also examined the potential correlation between single-trial amphetamine CPP and amphetamine self-administration.
With human subjects, the degree of self-reported positive reward
derived from the initial drug experience is related to drug abuse
vulnerability (Haertzen et al. 1983). To assess this predictive relationship in a controlled setting, individual differences in singletrial amphetamine CPP were correlated with subsequent rates of
amphetamine self-administration on an FR1 and PR schedule. Although the number of amphetamine self-infusions varied as a function of dose, we found no evidence that individual differences in
single-trial amphetamine CPP correlated with subsequent amphetamine self-administration rates under either the FR1 or PR schedule. Thus, these results in rats challenge the idea that individual differences in drug abuse vulnerability are related to the degree of
reward derived from the first drug experience.
Finally, any conclusion based upon the present correlational
results should be tempered because the CPP and self-administration paradigms are not equivalent measures of drug reward. While
there seems to be reasonable correspondence between these paradigms in their ability to identify drugs that have abuse liability (cf.
Yokel 1987; Carr et al. 1989), both methodological and theoretical differences have tended to prevent direct comparison of results
obtained with each paradigm. Recent evidence from monkeys indicates that the relationship between CPP and self-administration
is not completely concordant (Evans and Foltin 1997; Foltin and
Evans 1997). Evidence also indicates that the neural mechanisms
that underlie CPP and self-administration do not overlap completely (Bardo 1998). Thus, the failure to find any relationship between
single-trial amphetamine CPP and subsequent amphetamine selfadministration may be related to inherent differences between the
paradigms, rather than to differences in the acute and chronic rewarding effects of amphetamine.
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